Literature DB >> 10382639

Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?

S K So1, C O Esquivel, J C Imperial, G Garcia, H Monge, E B Keeffe.   

Abstract

To assess whether Asian race is an independent variable affecting survival and hepatitis B virus (HBV) recurrence after liver transplantation, the results of 27 consecutive liver transplants performed between June 1994 and April 1997 for HBV cirrhosis were analysed. In the group of 13 Asians, 38% had associated hepatocellular carcinoma and 62% had positive hepatitis B virus early antigen (HBeAg) or elevated HBV-DNA before transplant. Prophylactic hepatitis B immunoglobulin (HBIG) was administered perioperatively and long term at 4-6 weekly interval. Four patients with elevated HBV-DNA received lamivudine before transplantation. The 3 year actuarial patient survival rate was 100% in both Asian and non-Asian patients. Twenty-six patients remained seronegative for hepatitis B virus surface antigen after transplantation. The incidence of post-transplant HBV recurrence was similar: 0% in Asians compared with 7% in non-Asians. There was no recurrence in the group of 12 patients who were HBV-DNA or HBeAg negative pretransplant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382639     DOI: 10.1046/j.1440-1746.1999.01900.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients.

Authors:  Linda-L Wong; Whitney-M Limm; Naoky Tsai; Richard Severino
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.

Authors:  En Qiang Chen; Tao You Zhou; Li Liu; Cong Liu; Ming Lei; Hong Tang
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.